The effects of short-term and long-term testosterone supplementation on blood viscosity and erythrocyte deformability in healthy adult mice

Endocrinology (United States)

Volumn 156, Issue 5, 2015, Pages 1623-1629

  Guo, Wen ^a   Bachman, Eric ^b   Vogel, Johannes ^c   Li, Michelle ^a   Peng, Liming ^a   Pencina, Karol ^a   Serra, Carlo ^a   Sandor, Nicolae L ^a   Jasuja, Ravi ^a   Montano, Monty ^a   Basaria, Shehzad ^a   Gassmann, Max ^c   Bhasin, Shalender ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b ALEXION PHARMACEUTICALS   (United States)

^c UNIVERSITY OF ZURICH   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE PROPIONATE; ANDROGEN; TESTOSTERONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; CANCER PATIENT; CASTRATED FEMALE; CASTRATED MALE; CONTROLLED STUDY; DRUG MEGADOSE; ERYTHROCYTE DEFORMABILITY; FEMALE; HEMATOCRIT; HORMONAL THERAPY; INTERVENTION STUDY; LONG TERM CARE; LOW DRUG DOSE; MALE; MOUSE; MOUSE MODEL; NONHUMAN; PLASMA VISCOSITY; PRIORITY JOURNAL; PROSTATE CANCER; SHEAR STRESS; SHORT COURSE THERAPY; TESTOSTERONE BLOOD LEVEL; TREATMENT DURATION; ANIMAL; C57BL MOUSE; DRUG EFFECTS; ERYTHROCYTE; ORCHIECTOMY; TIME;

ANDROGENS; ANIMALS; BLOOD VISCOSITY; ERYTHROCYTE DEFORMABILITY; ERYTHROCYTES; FEMALE; MALE; MICE; MICE, INBRED C57BL; ORCHIECTOMY; TESTOSTERONE; TIME FACTORS;

EID: 84929018074     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1784     Document Type: Article

References (29)

1. Vigen R, O'Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310:1829-1836.
2. Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9:e85805.
3. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med. 2010;363: 109-122.
4. Yeap BB, Alfonso H, Chubb SA, et al. In older men an optimal plasma testosterone is associated with reduced all-cause mortality and higher dihydrotestosterone with reduced ischemic heart disease mortality, while estradiol levels do not predict mortality. J Clin Endocrinol Metab. 2014;99:E9-E18.
5. Soisson V, Brailly-Tabard S, Helmer C, et al. A J-shaped association between plasma testosterone and risk of ischemic arterial event in elderly men: the French 3C cohort study. Maturitas. 2013;75:282-288.
6. Smith BD, La Celle PL. Blood viscosity and thrombosis: clinical considerations. Prog Hemost Thromb. 1982;6:179-201.
7. Cowan AQ, Cho DJ, Rosenson RS. Importance of blood rheology in the pathophysiology of atherothrombosis. Cardiovasc Drugs Ther. 2012;26:339-348.
8. Jeong SK, Cho YI, Duey M, Rosenson RS. Cardiovascular risks of anemia correction with erythrocyte stimulating agents: should blood viscosity be monitored for risk assessment? Cardiovasc Drugs Ther. 2010;24:151-160.
9. Simmonds MJ, Meiselman HJ, Baskurt OK. Blood rheology and aging. J Geriatr Cardiol. 2013;10:291-301.
10. Bachman E, Feng R, Travison T, et al. Testosterone suppresses hepcidin in men: a potential mechanism for testosterone-induced erythrocytosis. J Clin Endocrinol Metab. 2010;95:4743-4747.
11. Bachman E, Travison TG, Basaria S, et al. Testosterone induces erythrocytosis via increased erythropoietin and suppressed hepcidin: evidence for a new erythropoietin/hemoglobin set point. J Gerontol A Biol Sci Med Sci. 2014;69:725-735.
12. Basaria S, Nguyen T, Rosenson RS, Dobs AS. Effect of methyl testosterone administration on plasma viscosity in postmenopausal women. Clin Endocrinol (Oxf). 2002;57:209-214.
13. Anderson FH, Francis RM, Faulkner K. Androgen supplementation in eugonadalmenwith osteoporosis-effects of 6 months of treatment on bone mineral density and cardiovascular risk factors. Bone. 1996;18:171-177.
14. Zhao C, Moondu G, Park JK. Effect of testosterone undecanoate on hematological profiles, blood lipid and viscosity and plasma testosterone level in castrated rabbits. Can Urol Assoc J. 2013;7:E221-E225.
15. Vogel J, Kiessling I, Heinicke K, et al. Transgenic mice overexpressing erythropoietin adapt to excessive erythrocytosis by regulating blood viscosity. Blood. 2003;102:2278-2284.
16. Judkiewicz L, Ciszewski R, Bartosz G. The effect of donor age on the packing susceptibility of erythrocytes. Mech Ageing Dev. 1988;46: 83-87.
17. Forconi S, Guerrini M, Ravelli P, et al. Arterial and venous blood viscosity in ischemic lower limbs in patients affected by peripheral obliterative arterial disease. J Cardiovasc Surg (Torino). 1979;20: 379-384.
18. Bhasin S, Zhang A, Coviello A, et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids. 2008;73:1311-1317.
19. Broulik PD. The effect of castration and androgen treatment on glomerular volume in mice. Exp Clin Endocrinol. 1983;82:115-117.
20. Guo W, Bachman E, Li M, et al. Testosterone administration in-hibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell. 2013;12:280-291.
21. Delev DP, Davcheva DP, Kostadinov ID, Kostadinova, II. Effect of testosterone propionate on erythropoiesis after experimental orchiectomy. Folia Med (Plovdiv). 2013;55:51-57.
22. Li RY, Cao ZG, Li Y, Wang RT. Increased whole blood viscosity is associated with silent cerebral infarction. Clin Hemorheol Microcirc. Published online ahead of print August 29, 2013. DOI: 10.3233/CH-131760.
23. Naets JP, Wittek M. The mechanism of action of androgens on erythropoiesis. Ann NY Acad Sci. 1968;149:366-376.
24. Kameneva MV, Garrett KO, Watach MJ, Borovetz HS. Red blood cell aging and risk of cardiovascular diseases. Clin Hemorheol Microcirc. 1998;18:67-74.
25. Gorodeski GI. Impact of the menopause on the epidemiology and risk factors of coronary artery heart disease in women. Exp Gerontol. 1994;29:357-375.
26. Henning P, Ohlsson C, Engdahl C, et al. The effect of estrogen on bone requires ERα in nonhematopoietic cells but is enhanced by ERα in hematopoietic cells. Am J Physiol Endocrinol Metab. 2014; 307:E589-E595.
27. Rochira V, Zirilli L, Madeo B, Maffei L, Carani C. Testosterone action on erythropoiesis does not require its aromatization to estrogen: insights from the testosterone and estrogen treatment of two aromatase-deficient men. J Steroid Biochem Mol Biol. 2009;113: 189-194.
28. Angelova P, Momchilova A, Petkova D, Staneva G, Pankov R, Kamenov Z. Testosterone replacement therapy improves erythrocyte membrane lipid composition in hypogonadal men. Aging Male. 2012;15:173-179.
29. Wang S, Dale GL, Song P, Viollet B, Zou MH. AMPKα1 deletion shortens erythrocyte life span in mice: role of oxidative stress. J Biol Chem. 2010;285:19976-19985.